Terms ending in 2028
Every in-force patent on Hoffmann-La Roche Inc.'s record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 7,662,990 | Process for Preparing Ibandronate In force · High confidence | Hoffmann-La Roche, Inc. | In force | High confidence | |
| US 8,809,005 | Conjugate and Its Use as a Standard in an Immunoassay In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 11,261,238 | Immunoglobulin Purification In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 9,933,433 | Anti-Drug Antibody Assay In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 9,926,567 | Promoter In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 9,121,067 | Predictive Marker for Egfr Inhibitor Treatment In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 8,507,535 | Methyl-Pyrrolidine Ether Derivatives In force · Medium confidence | Hoffmann-La Roche Inc. | In force | Medium confidence | |
| US 7,765,713 | Water Vapor Monitoring Apparatus In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 10,590,186 | Immunoglobulin Purification In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 9,428,766 | Protein Expression from Multiple Nucleic Acids In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| 9 more term ends in 2028 · Pro | |||||
10 of 19 patents shown. Soonest term end first, then patent number.
Pro members see all 19, including 2 expiring within the 18 months from Nov 18, 2026.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.